Poseida Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PSTX Nasdaq 8731 https://poseida.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Poseida Therapeutics Inc

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - Oct 3rd, 2024 8:30 pm
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - Sep 27th, 2024 8:30 pm
FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1 - Sep 17th, 2024 8:12 am
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma - Sep 16th, 2024 12:00 pm
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting - Sep 5th, 2024 1:00 pm
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma - Sep 4th, 2024 8:05 pm
Poseida Therapeutics to Present at Upcoming Investor Conferences - Aug 29th, 2024 8:05 pm
Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Aug 7th, 2024 12:57 pm
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates - Aug 5th, 2024 9:55 pm
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 - Aug 5th, 2024 8:05 pm
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains - Aug 5th, 2024 11:33 am
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice - Jul 19th, 2024 4:00 pm
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum - Jul 1st, 2024 8:05 pm
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - Jun 3rd, 2024 8:05 pm
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - May 14th, 2024 8:05 pm
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting - May 9th, 2024 1:00 pm
Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher - May 3rd, 2024 10:46 am
Xyphos and Poseida to develop allogeneic cell therapies for cancer - May 2nd, 2024 10:22 am
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology - May 2nd, 2024 1:30 am
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal - May 1st, 2024 9:42 am